Εξέλιξη φαρμακευτικών δαπανών στην Ελλάδα – Συγκρίσεις με χώρες στην ΕΕ
Evolution of pharmaceutical expenditure in Greece - Comparisons with the EU countries
Θεματική επικεφαλίδαΦαρμακευτική πολιτική -- Ελλάδα ; Φαρμακευτική πολιτική -- Ευρωπαϊκή Ένωση, χώρες της ; Φάρμακα -- Τιμές ; Pharmaceutical policy -- Greece ; Pharmaceutical policy -- European Union countries ; Drugs -- Prices
The purpose of this paper is to describe, economic valuation and evaluation of drug policies and actions that have been implemented in Greece and Europe today. It also seeks to explain the multifaceted factors that modulate the function of the medicine market. The health and in particular the pharmaceutical policy is one of the key issues facing modern societies, while also represents one of the most important sectors of the economy, contributing to employment and GDP of each country. Drugs have increased life expectancy, helping to eliminate diseases that were previously threatening human life. With the increase in life expectancy has decreased while the mortality, but more and more European citizens are affected by chronic diseases that while having less impact on mortality increase pharmaceutical costs greatly. Health and drug costs and how they will reduce a central point and the main objective of all health policy in developed countries in recent years. Especially in Greece pharmaceutical expenditure is increasing becoming the gangrene of pension funds are constantly under intensive efforts to curb. The update of the Memorandum of Economic Affairs set specific goals with respect to the maximum level of public health and drug costs. On the basis of these efforts have been announced or implemented a series of measures to curb these costs. In the context of this paper will explore the subject of the size of pharmaceutical expenditure and made a comparison between Greece and the EU countries. Initially considered necessary reference to the characteristics of the pharmaceutical market and pharmaceutical products and then proceed to the analysis of costs and policies in the EU with respect to the delivery of drugs. Below, in the third chapter analyzes the Greek pharmaceutical market, while the last chapter the comparison is made between the costs of the EU and Greece.